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ABSTRACT
Introduction: The duration of uncontrolled
type 2 diabetes mellitus (T2DM) can adversely
impact small and large vessels, eventually
leading to microvascular and macrovascular
complications. Failure of therapeutic lifestyle
changes, monotherapy, and clinical inertia
contribute to persistent hyperglycemia and
disease progression. The aim was to review the
complex pathophysiology of type 2 diabetes
and how different oral agents can be used
effectively as first-line therapy in combination
with metformin, as well as in patients not
achieving glycemic goals with metformin
therapy.
Methods: For this review, a non-systematic
literature search of PubMed, NCBI, and Google
Scholar was conducted.
Results: New oral agents have made it possible
to improve glycemic control to near-normal
levels with a low risk of hypoglycemia and
without weight gain, and sometimes with
weight loss. Early combination therapy is
effective and has been shown to have a
favorable legacy effect. A number of agents are
available in a single-pill combination (SPC) that
provides fewer pills and better adherence.
Compared with adding a sulfonylurea, still the
most common oral combination used,
empagliflozin has been shown to decrease
cardiovascular (CV) events in a dedicated CV
outcome study, and pioglitazone has been
effective in reducing the risk of secondary CV
endpoints, whereas sulfonylureas have been
associated with an increased risk of CV disease.
In those failing metformin, triple oral therapy
by adding a non-metformin SPC such as
empagliflozin/linagliptin or pioglitazone/
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alogliptin is a good option for reducing glycated
hemoglobin (HbA1c) without significant
hypoglycemia.
Conclusion: Clinicians have a comprehensive
armamentarium of medications to treat patients
with T2DM. Clinical evidence has shown that
dual or triple oral combination therapy is
effective for glycemic control, and early
treatment is effective in getting patients to
goal more quickly. Use of SPCs is an option
for double or triple oral combination therapy
and may result in better adherence.
Keywords: DPP-4 inhibitors; Early
combination therapy; Hyperglycemia;
Hypoglycemia; Oral glucose-lowering agents;
SGLT2 inhibitors; Single-pill combination;
Type 2 diabetes mellitus
INTRODUCTION
Over the last several decades, the diabetes
landscape has been transformed by an
improved understanding of its
pathophysiology and the development of an
array of antihyperglycemic medications [1]. Yet,
diabetes remains a pervasive disease with
immense public health consequences and
increasing prevalence of type 2 diabetes
mellitus (T2DM) in adults [2]. Despite the
number of treatment options, hyperglycemia
is still often poorly controlled [3], chiefly
reflecting the limitations inherent in
treatment options for T2DM and clinical
inertia. Lifestyle changes such as diet or
exercise are insufficient, and the efficacy of
pharmacologic agents is rarely sustained over
time and may be limited by side effects. After
prescribing therapeutic lifestyle changes, there
may be delays in initiating monotherapy, often
metformin, and physicians may wait long
periods of time (even years) before adding
additional therapy [4]. This step-up approach
is conducive to treatment failure; evidence from
monotherapy studies shows that long-term
glycemic control is often not durable [5, 6].
Several studies have stressed the importance of
early treatment, not only to prevent small vessel
disease complications, but to prevent
cardiovascular (CV) events years after the
completion of the trial (a result of the legacy
effect) as well [7–9].
The current therapeutic landscape also
results from caution based on potential
adverse events with available glucose-lowering
agents [4]. For example, insulins and
sulfonylureas (SUs) are associated with weight
gain and hypoglycemia [1], the latter being of
particular concern in the elderly [10]. The
management of T2DM may be facilitated with
single-pill combinations (SPC) by enabling
patients to take fewer pills per day, which may
lead to improved patient adherence [11]. Many
combinations include metformin and can be
used early in the disease. Two other SPCs,
pioglitazone/alogliptin and empagliflozin/
linagliptin, have shown good glucose-lowering
efficacy when added to metformin [12, 13].
It is important to choose agents that treat the
patient as a whole, not just their hyperglycemia.
For example, individuals with T2DM are at high
risk of CV disease and need aggressive therapy
that includes the management of concomitant
CV risk factors such as obesity, hypertension,
and dyslipidemia [14]. In addition, patients
with T2DM and chronic kidney disease (CKD)
are also at an increased risk of severe
hypoglycemia [15] and present a treatment
challenge. Metformin is not recommended for
use in patients with an estimated glomerular
filtration rate (eGFR) less than 45 mL/min/
1.732; however, metformin may be used safely
in patients with mild impairment in kidney
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function and with proper monitoring in
patients with moderate impairment in kidney
function [16]. As the number of newly
diagnosed patients with T2DM increases and
patients live longer, CKD needs to be a
consideration when choosing
antihyperglycemic agents. In the recently
published long-term follow-up to the Steno-2
trial of patients with T2DM and
microalbuminuria, more intensified,
multifactorial, target-driven treatment resulted
in an almost 8-year longer survival with fewer
CV complications [17]. Thus, a one-size-fits-all
approach to treat hyperglycemia is insufficient
and a patient-centered approach is necessary.
Herein, we describe the rationale for early
combination therapy, review the clinical
efficacy and safety data for the empagliflozin/
linagliptin SPC, and discuss how SPC therapy
can be used in a personalized approach. This
review discusses only oral agents as they are
more commonly used early in the disease. Of
the nine classes of oral medications listed in
Table 1, this paper focuses on the newer classes,
dipeptidyl peptidase 4 (DPP-4) inhibitors and
sodium glucose cotransporter 2 (SGLT-2)
inhibitors, available in the USA, as well as the
older SUs and thiazolidinediones (TZDs), agents
that are commonly prescribed when metformin
fails.
REVIEW METHODS
For this narrative review, a non-systematic
literature search was conducted on various
databases, including PubMed, NCBI, and
Google Scholar. The search terms included
type 2 diabetes, early treatment with oral
agents such as linagliptin, empagliflozin,
metformin, DPP-4 inhibitors, and fixed-dose
combination with linagliptin and
empagliflozin. Relevant references were
identified after screening the titles, and results
were then revised qualitatively on the basis of
treatment initiation time and use of
combination or fixed-dose therapy. Relevant
clinical trials evaluating early combination
therapy in patients with T2DM were identified
on ClinicalTrials.gov. Other sources included
drug manufacturers’ websites and references
known to the author.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
PATHOPHYSIOLOGY
T2DM is a complex disease with multiple
pathophysiologic components (Fig. 1).
Elevated blood glucose results from
insufficient insulin production and insulin
resistance, as well as a closely intertwined
dysfunction of many other metabolic and
hormonal pathways [18]. Impaired b cell
function and impaired insulin secretion are
hallmarks of T2DM. In addition, pancreatic
a cells secrete inappropriately high amounts of
glucagon in spite of hyperglycemia and
hyperinsulinemia, the two major factors that
decrease glucagon secretion and endogenous
glucose production. As a result, inappropriate
endogenous glucose production leads to fasting
hyperglycemia and also contributes to
postprandial hyperglycemia.
T2DM has evolved into a disorder that now
affects a younger population afflicted with
central obesity and abnormal adipocyte
function [19]. In addition, the gastrointestinal
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tract exhibits abnormal secretion of incretin
hormones, glucagon-like peptide 1 (GLP-1) and
glucose-dependent insulinotropic polypeptide
[18, 20]. These two hormones account for 90%
of the incretin effect, which plays a pivotal role
in maintaining normal glucose homeostasis.
The kidneys also play a crucial role in glucose
homeostasis by releasing glucose into the
circulation via gluconeogenesis, particularly
during fasting, and reabsorbing all of the
filtered glucose [21], both of which are
adaptive mechanisms that ensure sufficient
energy is available during fasting periods. The
transport protein, SGLT2, is a low-affinity,
high-capacity glucose transporter that
reabsorbs approximately 90% of filtered
glucose, while the high-affinity, low-capacity
SGLT1 transporter reabsorbs the remainder [22].
Table 1 Classes of oral medications for glycemic management approved in the USA [1, 24]
Class Compounds Primary physiologic action Hypoglycemia Weight
Biguanides Metformin ; Hepatic glucose production Neutral Slight
loss
Sulfonylureas Glyburide/glibenclamide
Glimepiride
Glipizide
: Insulin secretion Moderate/severe Gain
Meglitinides Repaglinide
Nateglinide
: Insulin secretion Mild Gain
Thiazolidinediones Pioglitazone
Rosiglitazone
: Insulin sensitivity Neutral Gain
a-Glucosidase
inhibitors
Acarbose
Miglitol
Slows carbohydrate digestion/absorption Neutral Neutral
DPP-4 inhibitors Alogliptin
Linagliptin
Sitagliptin
Saxagliptin
: Insulin secretion (glucose-dependent)
; Glucagon secretion (glucose-dependent)
Neutral Neutral
Bile acid
sequestrants
Colesevelam ; Hepatic glucose production (?)
: Incretin levels (?)
Neutral Neutral
Dopamine-2
agonists
Bromocriptine (quick
release)
Modulates hypothalamic regulation of
metabolism
: Insulin sensitivity
Neutral Neutral
SGLT2 inhibitors Canagliﬂozin
Dapagliﬂozin
Empagliﬂozin
Inhibit glucose reabsorption by the kidney
: Glucosuria
Neutral Loss
DPP-4 dipeptidyl peptidase-4, SGLT2 sodium glucose cotransporter 2
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A maladaptation takes place in individuals with
diabetes with increased expression and activity
of SGLT2 in the proximal tubule of the kidney.
As a result, glucose reabsorption increases by as
much as 20% in individuals with poorly
controlled diabetes, contributing to
hyperglycemia [22]. In T2DM and obesity, the
central nervous system fuel feedback is affected
by insulin and leptin resistance, further
contributing to glycemic dysregulation.
Individuals with obesity and T2DM are insulin
and leptin resistant and display
neurotransmitter dysfunction that alters the
normal fuel feedback to the brain [23], making
the central nervous system a critical player in
glucose dysregulation. In summary, complex
and multiple pathophysiologic disturbances
involving different organs and endocrine and
neurologic pathways cause hyperglycemia, and
therefore it is not surprising that a multitiered
treatment approach is necessary.
TREATMENT GUIDELINES
AND APPROACHES
Treatment guidelines developed by the
American Diabetes Association (ADA) and the
European Association for the Study of Diabetes
(EASD), as well as by the American Association
of Clinical Endocrinologists (AACE) and the
Fig. 1 Pathophysiologic abnormalities targeted by cur-
rently available antihyperglycemic medications. DPP4i
dipeptidyl peptidase 4 inhibitor, GLP1 RA glucagon-like
peptide 1 receptor agonist, HGP hepatic glucose produc-
tion, MET metformin, SGLT2i sodium glucose cotrans-
porter 2 inhibitor, TZD thiazolidinedione. ‘‘From the
triumvirate to the ominous octet: a new paradigm for the
treatment of type 2 diabetes mellitus’’. American Diabetes
Association, 2009. Copyright and all rights reserved.
Material from this publication has been used with the
permission of the American Diabetes Association
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American College of Endocrinology (ACE),
recommend metformin as the first-choice
pharmacotherapy if lifestyle changes, such as
diet and exercise, fail to achieve glycated
hemoglobin (HbA1c) goals within 3 months
[1, 24]. Metformin does not cause significant
hypoglycemia, is weight neutral, inexpensive,
and has a long-standing evidence base for
efficacy and safety [1]; it may even reduce the
risk of CV events [7]. On the basis of the
Diabetes Prevention Program study, metformin
is also recommended for individuals with
prediabetes, particularly those with a body
mass index greater than 35 kg/m2, aged less
than 60 years, and women with previous
gestational diabetes [25, 26]. If metformin is
contraindicated (e.g., because of decreased renal
function) or not tolerated, the AACE/ACE
guidelines suggest the use of one of the newer
agents, such as a GLP-1 receptor agonist, SGLT2
inhibitor, or DPP-4 inhibitor, over older agents
(a-glucosidase inhibitors, TZDs, and SUs) [24].
The ADA/EASD Position Statement does not
prioritize treatments and instead emphasizes
patient preference and individualized treatment
[1]. Individuals with T2DM benefit from
learning about managing their disease,
adopting a healthier lifestyle, and
understanding the pros and cons of their
medications. Well-structured education, such
as diabetes self-management education, should
aim to support informed decision-making,
problem-solving, and active collaboration with
the health care team to improve clinical
outcomes, health status, and quality of life in
a cost-effective manner [27, 28]. Monitoring
glycemic goals via determination of HbA1c
levels and self-monitoring of blood glucose
(SMBG) varies according to the individual and
his or her treatment [1].
DPP-4 Inhibitors
DPP-4 inhibitors are gastrointestinal peptides
that enhance secretion of insulin from
pancreatic b cells and suppress glucagon
release from pancreatic a cells in a
glucose-dependent manner [29]. DPP-4
inhibitors have a low risk of hypoglycemia, are
weight neutral, have been shown to improve
b cell function in animal and in vitro studies
[30, 31], and can exert several favorable effects
on the CV system, including improved
ventricular function [32]. Currently, four
DPP-4 inhibitors are approved in the USA for
the treatment of hyperglycemia alone or in
combination with other oral agents and insulin:
alogliptin, linagliptin, sitagliptin, and
saxagliptin (Table 2). In clinical trials, DPP-4
inhibitor monotherapy has been shown to
improve glycemic control with mean
reductions in HbA1c in the range of 0.6–1.1%
[33]. When used in patients with moderate or
severe CKD, alogliptin, saxagliptin, and
sitagliptin require a lower dose [34].
Linagliptin, the only DPP-4 inhibitor primarily
excreted via the hepatic route, does not require
any dose adjustment. All DPP-4 inhibitors are
well tolerated, but have been associated with an
increased frequency of stuffy nose or cough [35]
and some cases of severe and disabling
arthralgia have been reported more recently
[36]. Reports of pancreatitis and pancreatic
cancer with the use of incretinomimetics are
still under investigation [37].
SGLT2 Inhibitors
SGLT2 inhibitors exert their effects via the
kidney and their mechanism of action
involves inhibiting the SGLT2 protein in the
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proximal nephron, thereby reducing the
inappropriately increased glucose reabsorption
found in T2DM and increasing urinary glucose
excretion [38]. SGLT2 inhibitors have proven to
be effective not only in improving glycemic
management but also in decreasing weight and
reducing systolic blood pressure (BP), with a low
risk of hypoglycemia, except when used with
insulin or SUs [38]. They provide significant
reductions in HbA1c versus placebo and are
similarly efficacious when compared with most
standard oral agents in head-to-head trials [39].
Because this action is independent of insulin,
SGLT2 inhibitors may be used at any stage of
T2DM, even after insulin secretion has waned
significantly [38].
The SGLT2 inhibitors lead to increased risk
of genital mycotic infections, particularly in
women. Urinary tract infections have also
been reported to be more common in some
patient groups, such as older patients, but the
increase is less clear-cut than for genital
infections [40]. Use of SGLT2 inhibitors also
has the potential to cause hypotension and
other hypovolemic events because of osmotic
diuresis, particularly in older patients taking
loop diuretics. In addition, trials have shown
small increases in low-density lipoprotein
cholesterol and, although these can be
managed with appropriate treatment, the
long-term consequences are unclear.
Long-term trials to establish CV safety are
still ongoing for canagliflozin and
dapagliflozin [41]. Results from the
EMPA-REG OUTCOME trial showed a
significant CV risk reduction [42], decreased
CV and overall mortality, slower progression
of kidney disease, and lower rates of clinically
relevant renal events in patients with T2DM
and CV risk factors who were treated with
empagliflozin versus placebo in addition to
standard of care [43] (see ‘‘CV Risk’’ section).T
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Post-marketing reports of ketoacidosis have
emerged after the approval of SGLT2 inhibitors,
with a number of cases reporting minimal
elevation of blood sugar (i.e., euglycemic
ketoacidosis) [44]. The US Food and Drug
Administration (FDA) has subsequently issued
a warning alerting health care practitioners and
patients to the signs and symptoms of
ketoacidosis [45].
Combination Therapy
Current guidelines recommend combination
therapy in patients with elevated HbA1c levels
at diagnosis (ADA/EASD[9.0%; AACE/
ACE C7.5%) or after 3 months of monotherapy
if HbA1c goals are not achieved [1, 24]. To
address the lack of long-term studies assessing
the efficacy and safety of initial combination
therapy, the US National Institutes of Health
has sponsored the Glycemia Reduction
Approaches in Diabetes: A Comparative
Effectiveness (GRADE) study [46]. The trial
does not compare older combinations, such as
TZDs, or newer agents, such as the SGLT2
inhibitors, and is limited to comparing the
combination of metformin with DPP-4
inhibitors, GLP-1 receptor agonists, insulin, or
SUs. Until the GRADE trial is completed
(estimated 2020), only two randomized,
controlled, long-term studies (both 5 years) are
available. First, the Bypass Angioplasty
Revascularization Investigation 2 Diabetes
(BARI 2D) study compared two different
strategies, insulin secretagogues (mainly
insulin and SUs) versus insulin sensitizers
(mainly metformin and rosiglitazone). The
study showed that the insulin sensitizer
strategy not only achieved better glycemic
control but was also associated with less
hypoglycemia and less weight gain [47]. The
second trial, Rosiglitazone Evaluated for
Cardiovascular Outcomes and Regulation of
Glycaemia in Diabetes (RECORD), compared
metformin plus SU with metformin plus
rosiglitazone, and also found better glycemic
control with the combination of rosiglitazone
and metformin [48]. Since these are the only
two long-term randomized clinical trials
available, treatment decisions should be
patient-centered and include considerations
such as efficacy, cost, potential side effects,
weight, comorbidities, hypoglycemia risk, and
patient preferences [25].
Although many shorter-term trials have
compared dual therapy versus metformin
monotherapy, few long-term, head-to-head
studies have directly compared drugs as
add-on therapy. A comparative effectiveness
meta-analysis suggests that, overall, each new
class of non-insulin agents added to initial
therapy lowers HbA1c levels by approximately
1% [49]. These differences may be true in
clinical trials, however, in day-to-day practice
tremendous variability occurs among patients’
responses to medications.
CV RISK
Intensive Glucose Lowering
CV disease is the major cause of morbidity and
premature mortality and an important
contributor to the direct and indirect costs of
diabetes [50]. Benefits can be seen when multiple
risk factors (e.g., BP, weight, smoking cessation)
are addressed globally [51, 52]. Long-term clinical
trials have also shown that aggressive glycemic
treatment benefits CV outcomes years after the
studies have been completed [7–9, 52]. These
effects have beenclearly demonstrated inpatients
with type 1 diabetes mellitus (T1DM) in the
Diabetes Control and Complications Trial/
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Epidemiology of Diabetes Interventions and
Complications study (DCCT/EDIC) [53]. This
was also shown in patients with T2DM in the UK
ProspectiveDiabetes Study (UKPDS) [7], andmore
recently in the long-term follow-up of the
Veterans Affairs Diabetes Trial (VADT) in which
CVdisease improvementwas found 10 years after
the study end [8], the legacy effect [7]. Although
the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study found that intensive
therapy (targetingHbA1c\6.0%) in patients with
T2DM increased mortality compared with
standard therapy (targeting HbA1c 7.0–7.9%)
[54], the VADT and the Action in Diabetes and
Vascular Disease (ADVANCE) trials showed that
intensive glucose control did not increase
mortality [55, 56]. VADT showed a reduction in
CVevent rates years after the studywascompleted
(median follow-up, 5.6 years) [8]. However,
interventions at a later disease stage, such as
intensive treatment in those with heart and
kidney disease, can also produce a legacy effect
after aggressive multifactorial treatment
initiation. A recent follow-up to the Steno-2
trial, following patients for a mean of 21.2 years
after 7.8 years of intensified multifactorial
treatment in patients with T2DM and
microalbuminuria, demonstrated a median gain
of 7.9 life-years [17].
When metformin is not indicated or
tolerated, including in treatment-naı¨ve
individuals, the empagliflozin/linagliptin SPC
can be a good alternative. Although the
addition of an SU is the most common step
after metformin fails, these agents have been
associated with hypoglycemia, sometimes
requiring hospitalizations, particularly in the
elderly [10] and in those with polypharmacy
[57]. Observational cohort trials have also
shown a disadvantage of SUs in general
[58, 59], and when compared to DPP-4
inhibitors [60, 61].
Several CV outcomes trials have compared
DPP-4 inhibitors with placebo or other agents in
addition to the usual standard of care for
glycemic control and CV risk factors [62–64].
In the Saxagliptin Assessment of Vascular
Outcomes Recorded in Patients with Diabetes
Mellitus–Thrombolysis in Myocardial Infarction
(SAVOR-TIMI) 53 trial, which compared
saxagliptin versus placebo in T2DM patients
with either a history of established CV events or
at high risk of CV events (N = 16,492) over a
median of 2.1 years, the rates of the composite
primary endpoint [CV death, nonfatal
myocardial infarction (MI), or ischemic stroke]
were similar between the treatment groups
[hazard ratio (HR), 1.00; 95% confidence
interval (CI), 0.89–1.12; P\0.001 for
non-inferiority; P = 0.99 for superiority] [62].
However, saxagliptin showed a higher rate of
hospitalization due to heart failure (3.5%)
relative to placebo (2.8%; HR, 1.27; 95% CI,
1.07–1.51; P = 0.007) [62]. In the Examination
of Cardiovascular Outcomes with Alogliptin
versus Standard of Care (EXAMINE) trial,
which investigated alogliptin versus placebo in
patients with acute coronary syndrome over a
median of 1.5 years, alogliptin was non-inferior
to placebo for the primary composite endpoint
(CV death, nonfatal MI, or nonfatal stroke): HR,
0.96; upper boundary of the one-sided repeated
CI, 1.16; P\0.001 for non-inferiority; P = 0.32
for superiority [63]. Moreover, in a post hoc
analysis, the first hospitalization due to heart
failure occurred at similar rates in both
treatment groups (alogliptin, 3.1%, placebo,
2.9%; HR, 1.07; 95% CI, 0.79–1.46; P = 0.657)
[64]. The larger (N = 14,671) and longer
(median follow-up, 3.0 years) Trial Evaluating
Cardiovascular Outcomes with Sitagliptin
(TECOS) trial evaluated sitagliptin versus
placebo on top of usual care in patients at
least 50 years of age with T2DM and established
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CV disease [65]. The results reassuringly
demonstrated no increased risk versus placebo
for the primary composite CV endpoint of CV
death, nonfatal MI, nonfatal stroke, or
hospitalization for unstable angina (alogliptin,
9.6%, placebo, 9.6%; HR, 0.98; 95% CI,
0.88–1.09; P\0.001 for non-inferiority in the
per-protocol population; P = 0.65 for
superiority) and no increase in hospitalization
for heart failure [HR in the intent-to-treat
analysis: 1.00 (95% CI, 0.83–1.20); P = 0.98]
[65].
CV Outcomes Trials with SGLT2 Inhibitors
Ongoing clinical trials assessing the impact of
the SGLT2 inhibitors dapagliflozin and
canagliflozin in patients with T2DM at high
risk of CV complications include Dapagliflozin
Effect on CardiovascuLAR Events
(DECLARE-TIMI 58) [41] and CANagliflozin
cardioVascular Assessment Study (CANVAS)
[66, 67]. For empagliflozin, the recently
completed EMPA-REG OUTCOME trial is the
first dedicated CV outcome study to demonstrate
that a glucose-lowering agent can improve CV
endpoints and lower CV mortality as well as
all-cause mortality in patients with T2DM at
high risk of CV events [42]. It evaluated the
effects of empagliflozin (10 or 25 mg once daily
versus placebo) on top of standard of care on CV
outcomes in 7020 patients with T2DM at high
risk of CV disease. The primary outcome was a
composite of death from CV causes, nonfatal MI,
or nonfatal stroke (3-point major adverse
cardiovascular events or MACE) and was
significantly reduced with empagliflozin (HR,
0.86, 95% CI, 0.74–0.99; P\0.001 for
non-inferiority and P = 0.04 for superiority).
Empagliflozin resulted in significantly lower
rates of death from CV causes (HR, 0.62; 95%
CI, 0.49–0.77; P\0.001), hospitalization for
heart failure (HR, 0.65; 95% CI, 0.50–0.85;
P = 0.002), and death from any cause (HR,
0.68; 95% CI, 0.57–0.82; P\0.001). Among
patients receiving empagliflozin, there was an
increased rate of genital infection but no
increase in other adverse events.
CV Outcomes Trials with TZDs
The TZDs are among the most potent
insulin-sensitizing drugs available. Their use in
patients with T2DM has decreased mainly as a
result of the adverse CV outcomes attributed to
rosiglitazone [68]. Pioglitazone, the other agent
in this class, may reduce the risk of CV events,
including stroke [69]. The PROspective
PioglitAzone Clinical Trial In macro-Vascular
Events (PROactive) trial evaluated the addition
of pioglitazone to current therapy in patients
with T2DM and a history of macrovascular
disease (N = 5238). Although the trial failed to
meet its primary composite endpoint of death
from any cause, nonfatal MI, stroke, acute
coronary syndrome, leg amputation, coronary
revascularization, or revascularization of the
leg, a significant reduction in the composite
secondary endpoint was observed (death from
any cause, nonfatal MI, or nonfatal stroke: HR
0.84; 95% CI, 0.72–0.98; P = 0.027) [70]. In a
follow-up analysis, the pioglitazone reduced
rates of fatal or nonfatal stroke and the
composite of CV death, nonfatal stroke, or MI
among patients with a history of previous stroke
[69]. More recently, pioglitazone was also found
to lower the risk of stroke or MI in individuals
without diabetes who had insulin resistance
along with ischemic stroke or transient
ischemic attacks [71]. Although pioglitazone
has shown beneficial CV outcomes, other
studies with the long-term use of TZDs,
mainly rosiglitazone [48, 72], have shown no
superiority.
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SPC THERAPY
Individuals with T2DM are often exposed to
polypharmacy, not only because of the need for
multiple antihyperglycemic agents but also
because of additional medications for the
treatment of CV risk factors, including
hypertension, dyslipidemia, and other
comorbidities [73]. In the Diabetes and Aging
Study, which analyzed data from more than
46,000 patients with T2DM in the USA, the
mean number of prescribed medications was
4.2, with 14% of patients taking more than
seven medications [74]. Similarly large numbers
of medications were used by patients in the
UKPDS 35 prospective observational study and
the BARI 2D trials [47, 75]. Given the substantial
polypharmacy, strategies to improve adherence
are welcome in T2DM. As such, treatment with
an SPC can facilitate medication adherence,
with the goal of improving health outcomes.
Using SPCs simplifies the treatment regimen
by decreasing the number of pills and reducing
the frequency of administration. Studies show
that adherence is improved with administration
of one tablet per day versus multiple tablets per
day [76–81]. Greater improvements in glycemic
control have also been shown with an SPC
versus the same medications coadministered as
separate pills [77]. However, data directly
addressing the effects of antihyperglycemic
SPCs with respect to health care costs are quite
limited [82]. Some data suggest reduced health
care utilization and costs with an SPC versus
loose-pill regimens [11]—a paradox as many
formularies penalize SPCs with higher prices.
Prescribing an SPC limits dose flexibility, and
thus many physicians prefer using them as a
maintenance option rather than an initial
therapy. However, the SPCs currently available
for use in T2DM are formulated in a variety of
dosage combinations [83] (Table 2). Modern
antihyperglycemic SPCs are easy to tolerate,
easy to prescribe, require little or no dose
titration, are associated with a low risk of
hypoglycemia, and therefore need less
frequent blood glucose monitoring.
Efficacy is generally comparable between
SPCs and separate-pill combination therapy
[84]. Although randomized controlled studies
of SPCs are limited, most studies demonstrate
improved or equivalent efficacy of the SPCs
compared with the monotherapies [83].
Pharmacokinetic studies have demonstrated
bioequivalence for several SPCs with their
corresponding loose-pill regimens, including
those with metformin extended release (XR)
[e.g., Actoplus Met XR (Takeda
Pharmaceuticals America, Inc.), Kombiglyze
XR (AstraZeneca Pharmaceuticals, LP), and
Janumet XR (Merck Sharp & Dohme Corp.)]
[83]. Metformin, the most commonly found
agent in the SPC therapies currently available in
the USA, is effective in reducing blood glucose
levels, but some patients have difficulty
tolerating this agent because of adverse
gastrointestinal effects [85]. Despite these
adverse effects, metformin remains the most
commonly prescribed medication, both in
monotherapy and combination [86]. SPCs are
particularly useful when they can be taken once
daily, and there are many fixed-dose
combinations containing metformin XR
(Table 2), which also improves gastrointestinal
tolerability [83]. One pill a day facilitates
adherence [76].
As with metformin, SUs have also been used
extensively in SPC therapies, partly because
they have been available for many years and
partly because they are generic and thus
relatively inexpensive. The initial SPC was a
combination of metformin and an SU. It was
followed by an SU combined with a TZD, now
also available in a generic form (Table 2). These
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SPCs may be less frequently prescribed because
they are associated with the disadvantages of
SUs; namely, lack of glycemic durability,
hypoglycemia, and weight gain [25]. The third
type of SPC therapy contains neither metformin
nor an SU; these agents can be added to
metformin when metformin alone is no longer
sufficient. There are only two such SPCs
approved by the US FDA: pioglitazone/
alogliptin [Oseni (Takeda Pharmaceuticals
America, Inc.)] and empagliflozin/linagliptin
[Glyxambi (Boehringer Ingelheim
Pharmaceuticals, Inc.)] [87]. The combination
of dapagliflozin/saxagliptin was submitted for
FDA review, and the FDA has asked for
additional data.
Empagliflozin/Linagliptin SPC
When treatment with metformin alone is not
sufficient, the empagliflozin/linagliptin SPC can
provide better HbA1c reductions than
empagliflozin or linagliptin alone. In a
placebo-controlled study (n = 674), 61.8% and
57.8% of patients with baseline HbA1c of at
least 7.0% achieved an HbA1c of less than 7.0%
at week 24 with empagliflozin 25 mg/linagliptin
5 mg and empagliflozin 10 mg/linagliptin 5 mg,
respectively, versus 28.0–36.1% of patients who
were using any of the three agents alone [13].
Even greater HbA1c reductions were achieved in
individuals with a baseline HbA1c of at least
8.5%, and these improvements in glycemic
control were associated with weight loss and
reduced systolic BP [13].
The empagliflozin/linagliptin SPC may be a
good alternative when metformin is not
indicated or tolerated or in treatment-naı¨ve
individuals. In treatment-naı¨ve patients with
T2DM and moderate hyperglycemia (n = 677;
mean HbA1c, 8.0%), the proportion who
achieved HbA1c levels less than 7.0% at
24 weeks was higher with empagliflozin
25 mg/linagliptin 5 mg (55.4%) and
empagliflozin 10 mg/linagliptin 5 mg (62.3%)
versus empagliflozin alone (25 mg, 41.5%;
10 mg, 38.8%) or linagliptin alone (5 mg,
32.3%) [88]. In this trial, however, the
empagliflozin 25 mg/linagliptin 5 mg SPC was
not significantly better than empagliflozin
25 mg alone. When compared with linagliptin
5 mg alone, both SPC doses significantly
reduced HbA1c, suggesting that without
metformin the glucose reduction is mostly
driven by empagliflozin [88]. Body weight
reductions with the SPCs were also similar to
empagliflozin alone, as were systolic BP
reductions from baseline (2.1–2.5 mmHg) and
a low incidence of hypoglycemia.
In both of these trials, events consistent with
urinary tract infections occurred at comparable
rates across all groups (10–16%), and events
consistent with genital infection were present
in 2–8.5% of patients, mostly women. In
summary, the empagliflozin/linagliptin SPC is
well tolerated, may cause a modest weight loss
with lower systolic BP, and has a low rate of
hypoglycemia.
Pioglitazone/Alogliptin SPC
Another available SPC is pioglitazone plus
alogliptin. In drug-naı¨ve patients, the
combination with pioglitazone 30 mg/
alogliptin 25 mg resulted in greater reductions
in HbA1c (-1.7 ± 0.1% from an 8.8% mean
baseline) versus pioglitazone 30 mg
(-1.2 ± 0.1%, P\0.001) or alogliptin 25 mg
(-1.0 ± 0.1%, P\0.001) alone [89]. When
added to metformin, the pioglitazone/
alogliptin SPC was also well tolerated and
effective [12]. When administered to
individuals with HbA1c 7.5–10.0% receiving at
least 1500 mg/day of metformin, pioglitazone
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plus metformin (pooled group) achieved a
mean HbA1c reduction from baseline of 0.9%.
In contrast, participants receiving triple therapy
(alogliptin, pioglitazone, and metformin)
achieved a mean HbA1c reduction of 1.4%
(P\0.001 versus the pioglitazone plus
metformin pooled group).
CONCLUSIONS
Antihyperglycemic SPCs have been developed
in an effort to address the issues of adherence
associated with combination pharmacotherapy
for patients with T2DM, with the goal of
optimizing clinical outcomes. Most SPCs
contain metformin or an SU. On the basis of
current guidelines, metformin is the preferred
choice for one of the agents in combination
therapy. The use of SUs is less desirable because
of weight gain, hypoglycemia, and potential CV
risks. When considering orally administered
alternatives or additions to metformin
therapy, agents with a low risk of
hypoglycemia that provide weight neutrality
or weight loss and have a proven CV safety
profile are preferred.
In the USA, two non-metformin
combinations are available,
alogliptin/pioglitazone and linagliptin/
empagliflozin. Both combinations contain
DPP-4 inhibitors, which are associated with
weight neutrality. However, when used in
combination, linagliptin/empagliflozin is
associated with weight loss due to the SGLT2
component, and alogliptin/pioglitazone is
associated with weight gain due to the TZD
component. These combinations are associated
with a low risk of hypoglycemia (except when
used in conjunction with insulin or insulin
secretagogues). Neither combination has been
studied in a dedicated CV outcomes trial.
Several CV outcomes trials have been
completed for the individual glucose-lowering
agents. CV outcomes trials for sitagliptin,
saxagliptin, and alogliptin have shown no
increased risk of overall CV events. EMPA-REG
OUTCOME is the only trial that has
demonstrated that adding empagliflozin causes
a reduction in major adverse CV events,
all-cause mortality, CV mortality, and heart
failure, as well as an improvement in renal
outcomes, when compared to treatment
placebo on top of the current recommended
standard of care [42, 43]. In a post hoc analysis
pioglitazone has also been found to have
favorable CV outcomes when used for
secondary intervention when compared to
placebo [69, 70]. In summary, we now have
different choices in the selection of oral agents
available for management of hyperglycemia.
While the treatment choice needs to be
patient-centered, we now have medications
that in addition to glycemic control also
reduce CV outcomes.
Early diagnosis of T2DM and aggressive
glycemic treatment may help preserve b cell
function. In addition, clinical studies suggest
that aggressive and early glycemic therapy
reduces complications, and the use of lifestyle
changes together with initial combination
therapy is recommended. Clinicians now have
a choice of what to use initially with
metformin, or what to add when metformin
fails. Newer combinations are weight neutral or
may provide weight loss. Adding an SPC may
improve adherence by decreasing the number
of pills needed. Finally, the cost of expensive
newer medications must be measured along
with the potential costs of complications
associated with older medications. For
example, sulfonylureas are associated with
hypoglycemia, and medical interventions for
634 Diabetes Ther (2016) 7:621–639
hypoglycemia often require more monitoring
and sometimes costly hospitalizations [90].
In managing diabetes, early diagnosis and
treatment with better lifestyles and proper
medications can normalize HbA1c without
hypoglycemia and/or weight gain. The use of
SPC therapy is recommended for better
adherence, and a more aggressive early
treatment should result in fewer complications
and a better quality of life. Consideration is
needed in every case to provide a
patient-centered approach that treats the
patient as a whole. This necessarily includes
taking into account concomitant risk factors
such as obesity, hypertension, dyslipidemia,
and renal impairment, as well as addressing
medication risk–benefit profiles and costs, when
making treatment choices.
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